Alliancebernstein Reduces Stake in Halozyme Therapeutics

Biopharmaceutical firm sees institutional investor trim holdings by over 22%

Mar. 17, 2026 at 7:09am

Got story updates? Submit your updates here. ›

Alliancebernstein L.P. has reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 22.3% during the third quarter, according to a recent 13F filing with the Securities & Exchange Commission. The investment firm previously owned 1,907,355 shares of the biopharmaceutical company's stock, valued at $139,885,000, but has now sold 547,913 shares.

Why it matters

Institutional investors like Alliancebernstein closely monitor and adjust their positions in biotech companies like Halozyme, which is developing novel drug delivery technologies. Changes in major shareholder stakes can signal shifts in market sentiment or the company's outlook.

The details

According to the 13F filing, Alliancebernstein now owns 1.62% of Halozyme Therapeutics' outstanding shares. The firm cited unspecified reasons for reducing its position in the company during the third quarter. Halozyme is known for its ENHANZE® technology platform, which enables subcutaneous administration of biologic therapies.

  • Alliancebernstein reduced its Halozyme Therapeutics stake during the third quarter of 2026.

The players

Alliancebernstein L.P.

A global investment management firm that previously owned a 1.62% stake in Halozyme Therapeutics.

Halozyme Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California that specializes in drug delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

Institutional investors like Alliancebernstein closely monitor biotech companies, and changes in their holdings can provide insights into market sentiment and the company's outlook. Halozyme's drug delivery platform continues to attract interest, but this stake reduction suggests some uncertainty around the firm's prospects.